Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases
Ko, N., Knauf, F., Jiang, Z., Markovich, D
A common research protocol: BPC-157: 250500 mcg daily (subcutaneous near injury) TB-500: 2.5 mg twice weekly (subcutaneous) Duration: 48 weeks The Bottom Line Neither peptide is universally "better" they excel in different contexts and work through different mechanisms
Proceedings of the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology 24 ChungS.Mc DonaldK
Acta Cardiol Sin 32, 631639
Their effects on metabolism, insulin sensitivity, and cellular growth require close monitoring and responsible use